Brief: Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
10/11/2022 21:50
Nov 10 (Reuters) - Adverum Biotechnologies Inc ADVM.O :
* ADVERUM BIOTECHNOLOGIES REPORTS THIRD QUARTER 2022
FINANCIAL
RESULTS
* ADVERUM BIOTECHNOLOGIES INC- CASH RUNWAY INTO 2025
PRIORITIZING
IXO-VEC CLINICAL DEVELOPMENT IN WET AGE-RELATED MACULAR
DEGENERATION (WET AMD)
* ADVERUM BIOTECHNOLOGIES INC- CASH, CASH EQUIVALENTS AND
SHORT-TERM INVESTMENTS WERE $203.3 MILLION AS OF SEPTEMBER 30,
2022
* ADVERUM BIOTECHNOLOGIES INC - QTRLY NET LOSS WAS $40.1
MILLION,
OR $0.40 PER BASIC AND DILUTED SHARE
Source text for Eikon: ID:nGNX3HKQPn
Further company coverage: ADVM.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Adverum Biotechnologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Adverum Reminds Stockholders To Tender Their Shares Into The Offer By Lilly
Brief: Adverum Biotechnologies Inc - Are-Nc Region No. 21 Llc Terminates Certain Lease Agreement With Adverum Biotechnologies - SEC Filing
Eli Lilly bets on eye care with buyout of gene therapy developer Adverum (updated)